(E)-4,4-dimethyl-1-propan-2-yloxypent-2-ene | 1041865-72-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (E)-4,4-dimethyl-1-propan-2-yloxypent-2-ene
• CAS: 1041865-72-8
• 化学式: C₁₀H₂₀O
• 分子量: 156.268
• InChiKey: QNZQLOVVIBSKDC-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-叔丁基丙二烯 、 异丙醇 在 silver trifluoromethanesulfonate 作用下， 反应 12.0h， 以38%的产率得到(E)-4,4-dimethyl-1-propan-2-yloxypent-2-ene
  参考文献：
  名称：

  金催化的烯类分子间加氢烷氧基化反应；加氢烷氧基化和加氢胺化机理的差异

  摘要：

  在ClAuPPh 3 / AgOTf催化剂的存在下，在没有溶剂的情况下，各种各样的醇2与各种丙二烯1反应，生成烯丙基醚3。与通过手性烯丙基的高手性面选择性产生相应手性烯丙基胺的加氢胺化相反，在加氢烷氧基化中未观察到手性的转移，这表明金催化加氢烷氧基化的机理与加氢胺化不同。

  DOI：

  10.1016/j.tetlet.2008.05.152

文献信息

• Benzimidazole derivatives
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10017499B2

  公开（公告）日：2018-07-10

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式（I）化合物或其药学上可接受的盐、酯或原药： 它们能抑制含 RNA 的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物可干扰丙型肝炎病毒的生命周期，也可用作抗病毒药物。本发明进一步涉及包含上述化合物的药物组合物，用于给丙型肝炎病毒感染者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者感染 HCV 的方法。
• LINKED DIBENZIMIDAZOLE DERIVATIVES
  申请人：Or Yat Sun

  公开号：US20100221214A1

  公开（公告）日：2010-09-02

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• HEPATITIS C VIRUS INHIBITORS
  申请人：Or Yat Sun

  公开号：US20100260715A1

  公开（公告）日：2010-10-14

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：Qiu Yao-Ling

  公开号：US20120076756A1

  公开（公告）日：2012-03-29

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US20140341851A1
  申请人：——

  公开号：US20140341851A1

  公开（公告）日：2014-11-20